PMC:7228307 / 48626-48997
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
|---|---|---|---|---|---|---|
| 967 | 307-315 | Gene | denotes | FcγRIIIa | Gene:2214 | |
| 968 | 14-26 | Chemical | denotes | ocaratuzumab | MESH:C550337 | |
| 969 | 118-125 | Disease | denotes | cancers | MESH:D009369 | |
| 970 | 137-157 | Disease | denotes | non‐Hodgkin lymphoma | MESH:D008228 | |
| 971 | 162-190 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
| 972 | 212-217 | Mutation | denotes | P247I | p.P247I | |
| 973 | 222-227 | Mutation | denotes | A339Q | p.A339Q |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T392 | 170-181 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T92 | 137-157 | Disease | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0011508|http://purl.obolibrary.org/obo/MONDO_0018908 |
| T94 | 141-157 | Disease | denotes | Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0004952 |
| T95 | 149-157 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
| T96 | 162-190 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
| T97 | 170-190 | Disease | denotes | lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0005402 |
| T98 | 182-190 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T99 | 345-349 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T833 | 33-35 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T834 | 107-108 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T835 | 191-193 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
| T836 | 198-200 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T837 | 307-309 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
|---|---|---|---|---|---|---|
| 967 | 307-315 | Gene | denotes | FcγRIIIa | Gene:2214 | |
| 968 | 14-26 | Chemical | denotes | ocaratuzumab | MESH:C550337 | |
| 969 | 118-125 | Disease | denotes | cancers | MESH:D009369 | |
| 970 | 137-157 | Disease | denotes | non‐Hodgkin lymphoma | MESH:D008228 | |
| 971 | 162-190 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
| 972 | 212-217 | Mutation | denotes | P247I | p.P247I | |
| 973 | 222-227 | Mutation | denotes | A339Q | p.A339Q |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T280 | 0-371 | Sentence | denotes | The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1. |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T605 | 9-13 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T391 | 170-181 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T115 | 345-349 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T40 | 137-157 | Disease | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0018908 |
| T41 | 162-190 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
LitCovid-sample-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T36 | 137-157 | Phenotype | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/HP_0012539 |
| T37 | 162-190 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T115 | 345-349 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T115 | 345-349 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T280 | 0-371 | Sentence | denotes | The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T36 | 137-157 | Phenotype | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/HP_0012539 |
| T37 | 162-190 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |